Omeprazole and Gastroprotectants in Dogs: ACVIM Consensus, Overprescription Evidence, and Gastrin Effects

Bottom line

• Proton pump inhibitors (PPIs) are the most commonly prescribed gastroprotectant in small animal practice (50.6% of participants in a 265-vet Spanish survey), yet overprescription remains documented as a significant concern.1
• The 2018 ACVIM consensus statement on rational use of gastrointestinal protectants significantly improved evidence-based omeprazole prescribing in an academic hospital: appropriate prescriptions increased and 94% of prescribers reported changing their practice after reading the consensus.2
• Long-term omeprazole administration in healthy dogs is associated with a statistically significant increase in serum gastrin levels (p=0.008) without significant changes in cobalamin concentrations over 60 days in a controlled trial.3
• Routine gastroprotection for all NSAID-treated dogs lacks robust evidence and is explicitly discouraged by the ACVIM consensus; use should be targeted to documented evidence-based indications.2

A specific patient on gastroprotectants?

Get an instant cited answer - no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=omeprazole-gastroprotectants-dogs

What the evidence shows

Overprescription and the ACVIM consensus

In human medicine, overprescription of proton pump inhibitors is a recognised quality indicator. In veterinary medicine, the same concern applies. A 265-veterinarian survey conducted in Spain documented prescribing habits for gastroprotectants in dogs: PPIs were the most commonly prescribed class (50.6% of participants), and while most main indications were supported by scientific evidence, injudicious use for conditions lacking robust evidence or recommendations was well documented.1 Veterinarians with fewer years of experience and those in internal medicine, emergency, and anaesthesia were more likely to adhere to evidence-based guidelines.

The American College of Veterinary Internal Medicine (ACVIM) published a consensus statement in 2018 on the rational administration of gastrointestinal protectants in dogs and cats. A before-and-after comparison at a Spanish academic veterinary hospital measured its impact: omeprazole prescriptions aligned with ACVIM-supported indications increased significantly (p<0.0001) in the post-consensus period (2021 vs 2017).2 Fifteen of 16 prescribing clinicians (94%) reported that reading the consensus changed their clinical practice regarding PPI administration. Frequency of appropriate tapering after >=4-week therapy also increased significantly after publication.

Pharmacodynamic monitoring: gastrin and cobalamin

A prospective randomised controlled trial enrolled 18 healthy dogs (10 control, 8 omeprazole-treated) and collected samples at baseline, 30 days, and 60 days.3 Key findings: serum gastrin concentrations rose significantly in the omeprazole group (median 67.59 pg/mL at baseline vs 191.77 pg/mL at T1, p=0.008), a known rebound hypergastrinaemia response to acid suppression. Cobalamin concentrations showed no statistically significant change in either group across the study period, contrasting with findings in human medicine where PPI-induced B12 deficiency has been documented. These findings suggest that in dogs, the cobalamin concern applies less directly than in humans, but that gastrin elevation - with its potential for rebound hyperacidity and long-term mucosal effects - warrants monitoring in prolonged use.

Evidence-based indications and appropriate use

The ACVIM consensus identifies specific indications warranting gastroprotection, including documented gastroduodenal ulceration, haemorrhagic gastroenteritis with endoscopic/biopsy confirmation, parvoviral enteritis, and administration with ulcerogenic drugs when additional risk factors are present. Routine prophylaxis for all NSAID-treated dogs is not evidence-supported and is explicitly discouraged. The consensus also emphasises that over-the-counter availability of omeprazole in many markets increases the likelihood of owner-initiated overprescription, making veterinary education a priority.

How this fits clinical practice

For the practising small animal clinician, the evidence supports a targeted approach to gastroprotection: reserve PPIs for established evidence-based indications, taper after >=4 weeks of therapy per the ACVIM consensus recommendation, and be alert to rebound hypergastrinaemia with prolonged use. The finding that an ACVIM consensus publication meaningfully shifted prescribing behaviour supports reviewing consensus updates as part of continuing education. Confirm current dosing, frequency, and drug interaction guidance with Plumb's Veterinary Drug Handbook; this page is an evidence summary, not a prescribing protocol.

Voyage Clinical Desk

From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=omeprazole-gastroprotectants-dogs

References

1. Olmeda P, Rey C, Rodriguez-Franco F, Marks SL, et al. Evaluation of Veterinary Prescription of Gastroprotectants in Dogs in Spain. Vet Sci. 2026;13(1):61. https://europepmc.org/articles/PMC12846710
2. Sainz A, Garcia-Sancho M, Villaescusa A, Rodriguez-Franco F, et al. Prevalence and appropriateness of omeprazole prescription in dogs at a veterinary teaching hospital before and after the publication of the ACVIM consensus statement. Front Vet Sci. 2024;11:1352496. https://europepmc.org/articles/PMC11107090
3. Gil-Vicente L, Martin G, Soler C, et al. Prospective Randomized Controlled Clinical Trial of the Long-Term Effects of Omeprazole on Healthy Dogs. Animals. 2024;14(8):1168. https://europepmc.org/articles/PMC11047556

Changelog

• 2026-06-19: First published.

Related reads

• Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence
• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence